JP2016519659A5 - - Google Patents

Download PDF

Info

Publication number
JP2016519659A5
JP2016519659A5 JP2016502225A JP2016502225A JP2016519659A5 JP 2016519659 A5 JP2016519659 A5 JP 2016519659A5 JP 2016502225 A JP2016502225 A JP 2016502225A JP 2016502225 A JP2016502225 A JP 2016502225A JP 2016519659 A5 JP2016519659 A5 JP 2016519659A5
Authority
JP
Japan
Prior art keywords
optionally substituted
use according
independently
alkyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016502225A
Other languages
English (en)
Japanese (ja)
Other versions
JP6579623B2 (ja
JP2016519659A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/026722 external-priority patent/WO2014151953A1/en
Publication of JP2016519659A publication Critical patent/JP2016519659A/ja
Publication of JP2016519659A5 publication Critical patent/JP2016519659A5/ja
Application granted granted Critical
Publication of JP6579623B2 publication Critical patent/JP6579623B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016502225A 2013-03-15 2014-03-13 軟骨形成を誘導するための化合物及び方法 Active JP6579623B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361794094P 2013-03-15 2013-03-15
US61/794,094 2013-03-15
PCT/US2014/026722 WO2014151953A1 (en) 2013-03-15 2014-03-13 Compounds and methods for inducing chondrogenesis

Publications (3)

Publication Number Publication Date
JP2016519659A JP2016519659A (ja) 2016-07-07
JP2016519659A5 true JP2016519659A5 (https=) 2017-04-13
JP6579623B2 JP6579623B2 (ja) 2019-09-25

Family

ID=51528123

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016502225A Active JP6579623B2 (ja) 2013-03-15 2014-03-13 軟骨形成を誘導するための化合物及び方法

Country Status (10)

Country Link
US (3) US9452170B2 (https=)
EP (1) EP2968330B1 (https=)
JP (1) JP6579623B2 (https=)
KR (1) KR102283996B1 (https=)
CN (3) CN116059196A (https=)
AU (1) AU2014236719B2 (https=)
CA (1) CA2904160C (https=)
ES (1) ES2900815T3 (https=)
HK (1) HK1224172A1 (https=)
WO (1) WO2014151953A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9464065B2 (en) * 2011-03-24 2016-10-11 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
HK1224172A1 (zh) 2013-03-15 2017-08-18 加州生物医学研究所 用於诱导软骨形成的化合物和方法
CN105294533A (zh) * 2015-12-02 2016-02-03 宋彤云 一种治疗骨病的药物组合物
KR20240045351A (ko) * 2016-11-14 2024-04-05 노파르티스 아게 연골 손상 및 관절염 치료 방법 및 조성물
EP3615021A4 (en) * 2017-04-24 2020-12-30 The Scripps Research Institute CHONDROGENESIS INDUCTION METHODS
UY37759A (es) 2017-06-09 2019-01-31 Novartis Ag Compuestos y composiciones para inducir condrogénesis
CN107056677A (zh) * 2017-06-19 2017-08-18 常州大学 一种3‑烷基2,3‑二氢异吲哚啉酮衍生物的合成方法
BR112020018832A2 (pt) * 2018-03-29 2021-02-09 Elex Biotech, Inc. compostos para o tratamento de arritimias cardíacas e insuficiência cardíaca
CN110937987B (zh) * 2018-09-25 2022-09-06 深圳市灵兰生物医药科技有限公司 一种化合物的合成路线及在抗糖尿病药物制备领域的应用
JP2022508751A (ja) * 2018-10-15 2022-01-19 ゲロ ディスカバリー リミテッド ライアビリティ カンパニー Pfkfb3阻害剤とその使用
CN109730999B (zh) * 2018-12-28 2021-12-24 中山大学 噻唑苯甲酰胺衍生在制备抗骨质疏松、抗骨关节炎药物中的应用
WO2020142865A1 (zh) * 2019-01-07 2020-07-16 江苏凯迪恩医药科技有限公司 一种苯甲酰胺类化合物、中间体、制备方法及应用
EP3946301A4 (en) * 2019-04-02 2023-08-09 The University of Chicago REMODILINS FOR RESPIRATORY TRACT REMODELING AND ORGAN FIBROSIS
BR112022026725A2 (pt) * 2020-08-05 2023-02-14 Lg Chemical Ltd Composição farmacêutica para aliviar ou tratar osteoartrite
CN114763347B (zh) * 2021-01-15 2024-06-21 华东师范大学 一类用于诱导间充质干细胞向软骨分化的化合物及其应用
CN114763346B (zh) * 2021-01-15 2025-06-10 华东师范大学 一类用于诱导软骨形成的化合物及其应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1016623A (en) 1911-09-06 1912-02-06 Harry Haller Jr Photographic-printing device.
CH489993A (de) 1967-12-19 1970-05-15 Ciba Geigy Das Pflanzenwachstum regulierendes und phytocides Mittel
FR2059977A1 (https=) 1969-08-14 1971-06-11 Socibre
KR0143565B1 (ko) * 1988-06-13 1998-07-15 사노 가즈오 피발산의 p-치환된 페닐 에스테르 유도체, 그의 제조 방법 및 이를 포함하는 조성물.
JPH0320253A (ja) * 1988-06-13 1991-01-29 Ono Pharmaceut Co Ltd ピバル酸 p―置換フェニルエステル誘導体、それらの製造方法およびそれらを有効成分として含有するエラスターゼ阻害剤
JPH0959236A (ja) 1995-08-23 1997-03-04 Dai Ichi Seiyaku Co Ltd ベンズアミド化合物
US5729014A (en) 1996-07-11 1998-03-17 Varian Associates, Inc. Method for injection of externally produced ions into a quadrupole ion trap
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
AU754830C (en) * 1997-05-22 2004-02-12 G.D. Searle Llc Substituted pyrazoles as p38 kinase inhibitors
US6040321A (en) 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
US6632961B1 (en) 1998-05-22 2003-10-14 Abbott Laboratories Antiangiogenic drug to treat cancer, arthritis and retinopathy
US6706712B2 (en) * 2000-12-20 2004-03-16 Bristol-Myers Squibb Pharma Company Cyclic derivatives as modulators of chemokine receptor activity
JP2005194191A (ja) * 2001-12-28 2005-07-21 Ajinomoto Co Inc 抗肥満薬、脂肪肝治療薬
WO2003075853A2 (en) * 2002-03-08 2003-09-18 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
US7288538B2 (en) 2003-02-20 2007-10-30 Encysive Pharmaceuticals, Inc. Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists
ATE355273T1 (de) 2003-05-12 2006-03-15 Pfizer Prod Inc Benzamidinhibitoren des p2x7-rezeptors
AU2004262494B2 (en) * 2003-07-29 2009-01-15 Universitaetsklinikum Muenster Means and methods for treating a disease which is associated with an excess transport of hyaluronan across a lipid bilayer
US7163937B2 (en) 2003-08-21 2007-01-16 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
US7863317B2 (en) * 2003-08-21 2011-01-04 Bristol-Myers Squibb Company Lactams of alkylated acyclic diamine derivatives as modulators of chemokine receptor activity
US20070054916A1 (en) * 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
US7776869B2 (en) * 2004-10-18 2010-08-17 Amgen Inc. Heteroaryl-substituted alkyne compounds and method of use
MX2007006790A (es) * 2004-12-07 2007-08-15 Toyama Chemical Co Ltd Novedosos derivado de acido antranilico o sal del mismo.
KR100787131B1 (ko) * 2006-07-04 2007-12-21 한국생명공학연구원 Hif―1 활성을 저해하는 화합물, 이의 제조방법 및이를 유효성분으로 함유하는 약학적 조성물
US8569378B2 (en) 2007-07-20 2013-10-29 Toshiyuki Sakai p27 protein inducer
WO2009043495A1 (en) * 2007-10-05 2009-04-09 Sanofi-Aventis Deutschland Gmbh Use of sulfonyl-substituted 2-sulfonylaminobenzoic acid n-phenylamides in the treatment of pain
US8143269B2 (en) * 2008-10-03 2012-03-27 Calcimedica, Inc. Inhibitors of store operated calcium release
JP5602850B2 (ja) 2009-07-14 2014-10-08 ザ スクリプス リサーチ インスティテュート 間葉幹細胞分化
HRP20150987T1 (hr) * 2010-05-26 2015-10-23 Adverio Pharma Gmbh UPORABA sGC STIMULATORA, sGC AKTIVATORA, SAMOSTALNO I U KOMBINACIJAMA S INHIBITORIMA PDE5 ZA LIJEÄŚENJE SISTEMSKE SKLEROZE (SSc)
US9464065B2 (en) 2011-03-24 2016-10-11 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
HK1224172A1 (zh) 2013-03-15 2017-08-18 加州生物医学研究所 用於诱导软骨形成的化合物和方法
DK3143026T3 (da) 2014-05-13 2024-09-30 Novartis Ag Forbindelser og sammensætninger til induktion af chondrogenese

Similar Documents

Publication Publication Date Title
JP2016519659A5 (https=)
IL275348B2 (en) Carbamoyl cyclohexyl acids linked via n triazole as lpa antagonists
MX2021000887A (es) Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer.
JP2015537020A5 (https=)
MX2020006599A (es) Composiciones y metodos para el tratamiento de trastornos en el sistema nervioso central.
MY194087A (en) Use of gabaa receptor reinforcing agent in preparation of sedative and anesthetic medicament
EP2650293A8 (en) [1,2,4]triazolo[4,3-b][1,2,4]triazine compound, preparation method and use thereof
MX2018004364A (es) Acidos pirazolo [3,4-b] piridin-6-carboxilicos sustituidos y su uso.
ECSP066730A (es) Compuestos y procedimientos para uso
DOP2013000191A (es) Derivados de heteroarilo como modulares de nachr alfa 7
UY29503A1 (es) Derivados de amida sustituida y metodos de uso
IN2014CN03803A (https=)
BR112014029016A2 (pt) derivados de ácido 7-oxo-tiazolopiridina carbônico e seu uso no tratamento, melhora ou prevenção de uma doença viral
BR112014008412A2 (pt) derivados de pirimidin-4-ona e sua utilização no tratamento, na melhora ou na prevenção de uma doença viral
NZ721645A (en) Compounds for use as gpr120 agonists
WO2013096429A3 (en) Methods and compositions for reducing body fat and adipocytes
CL2016000816A1 (es) Forma de dosificación que comprende al compuesto (s)-3-(4-((4-morfolinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2,6-diona, una cantidad de 90 hasta 99,9 por ciento en peso del peso total de una mezcla de almidón y lactosa como portador o excipiente, y acido esteárico como lubricante; su uso en el tratamiento de cáncer y enfermedades autoinmunes, entre otras.
MX2016011105A (es) Inhibidores de monoacilglicerol aciltransferasa 2 (mgat2) de dihidropiridinona para usarse en el tratamiento de trastornos metabolicos.
BR112022001568A2 (pt) Composto, método para preparação do composto, composição farmacêutica, e, uso do composto
PH12019500618A1 (en) Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease
PH12013501117A1 (en) Novel compound and medical use thereof
JP2015502371A5 (https=)
CO6361996A2 (es) 5- (2-{ [6- (2, 2-difluoro-2-feniletoxi) hexil] amino} -1-hidroxietil) -8-hidroxiquinolin-2 (ih)-ona y su uso en el tratamiento de enfermedades pulmonares
NI200900161A (es) Sales de adición de ácido, hidratos y polimorfos de la etil - amida del ácido 5 - (2,4 -dihidroxi -5- isopropil - fenil) -4- (4-morfolin-4-il-metil-fenil)-isoxazol-3-carboxílico, y formulaciones que comprenden estas formas.
UY28896A1 (es) Formulaciones en polvo para la inhalación , las cuales contienen beta-agonistas enantioméricamente puros